Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?
Bergh
Jonas
J
Radiumhemmet, Karolinska Institute and Hospital, S-171 76, Stockholm, Sweden. jonas.bergh@cck.ki.se <jonas.bergh@cck.ki.se>
D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008875:Middle Aged; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D016588:Anticarcinogenic Agents; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride